CANCER BIOLOGY

Dietmar W. Siemann, PhD
Professor and Associate Chair for Research
Leader, Experimental Therapeutics Program, University of Florida Shands Cancer Center

Educational Background

  • PhD, University of Toronto
  • BSc, University of Manitoba

Honors and Awards

  • 18th Recipient, Research Award of the Radiation Research Society, 1990
  • Chairman and Member, National Cancer Institute (NCI) Radiation Study Section, 1994-1998
  • John P. Cofrin Professor for Research in Radiation Oncology, 1999-present
  • Raymond S. Bush Visiting Professorship, University of Toronto, 2000
  • University of Florida Research Foundation Professorship, 2001-2003
  • University of Florida Professor Merit Award, 2004
  • University of Florida Student Mentor Award, 2005
  • University of Florida School of Medicine Basic Science Research Award, 2006
  • British Medical Association Medical Book Competition Award, 2007
  • University of Florida Research Foundation Professorship, 2008-2010
  • Robert F. Kallman Visiting Professorship, Stanford University, 2009

Publications available through PubMed


Research Areas

The tumor microenvironment has long been identified as a major factor influencing treatment resistance of cancer to conventional anticancer therapies. In addition it is now well recognized that the tumor microenvironment plays a critical role in neoplastic cell initiation, malignant progression, and metastatic spread of tumor cells. However, the very characteristics of the tumor microenvironment that lead to therapy resistance also can provide unique treatment opportunities. A major focus of this laboratory is the development and assessment of novel anticancer treatment strategies. This research emphasizes approaches targeting two critical aspects of cancer growth; the initiation of a tumor blood vessel network, and the secondary spread of cancer cells.

Current laboratory projects focus on:

These laboratory investigations utilize a variety of human and rodent preclinical cancer models, with particular emphasis on models of kidney, prostate, colorectal, and breast cancer. The research emphasizes translational medicine in oncology with the ultimate goal developing and advancing new treatment strategies for the clinical management of cancer.